The Industry’s Most Comprehensive End-to-End TCE Forum
If advancing your T‑cell engager (TCE) pipeline is a strategic priority for 2026, the 8th T‑Cell Engager Therapeutics Summit, taking place June 23–25 in San Diego, CA, is the one event you cannot afford to miss. Recognized as the field’s most comprehensive end‑to‑end meeting, this summit brings together discovery, engineering, translational, and clinical development experts to push the boundaries of TCE design, safety, durability, and translatability.
This year’s program is built to equip teams with actionable, deeply technical insights spanning the full TCE development arc, helping you engineer safer, more potent, longer‑lasting and precisely targeted therapies for solid tumors, while also exploring how engager biology is expanding into autoimmune and inflammatory diseases.
Take your first look at the 2026 agenda today: https://ter.li/c3lzxb
What’s New in 2026
Two Brand‑New Parallel Conference Tracks
For the first time, attendees can tailor their learning experience across two specialized content streams:
- Discovery & Engineering
- Preclinical to Clinical Translation
This dual‑track structure lets you dive deeper into the exact technical, mechanistic, and translational challenges aligned with your role, your modality, and your development stage.
Expanded Focus on Combination Strategies & Precision Immunotherapy
As combination regimens redefine immuno‑oncology, leading developers, including Amgen and Regeneron, will present fresh clinical data on:
- Chemo‑immunotherapy integration
- Co‑stimulation pairings
- Principles of designing “combination‑ready” TCEs
- Emerging evidence supporting deeper, more durable responses in solid tumors
With multiple approvals validating TCEs’ clinical durability and next‑generation solid tumor and autoimmune programs rapidly advancing, the field is experiencing unprecedented momentum. High‑impact collaborations, such as the notable BMS–Janux partnership, continue to underscore the modality’s expanding therapeutic promise.
2026 Highlights: What You’ll Gain
This year’s curriculum has been shaped around the most urgent challenges facing TCE developers:
- Cutting‑Edge Clinical Insights
Hear from AstraZeneca and Cartography Bio on strategies to:
- Overcome target‑specific and tumor‑microenvironment‑driven resistance
- Minimize on‑target/off‑tumor toxicities
- Strengthen translational reliability and predictive validity
- IND‑Enabling and Safety Frameworks
Gain practical guidance from Jazz Pharmaceuticals, QLSF Biotherapeutics, Regeneron, and Zymeworks on:
- Dose selection and optimization
- Managing step‑up dosing and CRS mitigation
- Building strong IND‑ready packages
- Next‑Generation Engineering Platforms
Learn from EvolveImmune, Xencor, and Stereo Bio as they share the latest in:
- Multispecific TCE engineering
- CD2 co‑stimulation platforms
- Strategies to boost potency, persistence, and anti‑tumor durability
Your Must‑Attend TCE Meeting of the Year
Despite major scientific leaps, challenges remain across novel target validation, co‑stimulation integration, first‑in‑human dosing, combination design, and translational extrapolation. The 2026 agenda is specifically designed to help you overcome these bottlenecks with confidence.
This is your opportunity to connect with industry leaders, benchmark your strategy, and elevate the impact of your TCE programs.
